Prof.dr SVETLANA VUJOVIC is professor of internal medicine, endocrinologist, Director of Clinic for endocrinology, diabetes and diseases of metabolism, University Clinical center of Serbia, haed of the National Center for infertility,endocrinology of genderand endocrinology of cardiovascular systemin, Faculty of medicine, University of Belgrade.She is president of the Serbian menopause society and society for aging male, president of the Serbian society for endocrinology of gender, president of the Belgrade gender team. Also, I am board member of the International society for gynecological endocrinology, Board member of European society for gynecology, past board member of European and International menopause society.PAPERS: 516.BOOKS: Premenstrual syndrome; Transsexualism- endocrine aspects; Gender identity; Hirsutism; Stress and somatisation; Stress and disseases; Menopuase; Menopause and hormone therapy, Adaptation in biosociology; Man and the Universe; Human clinical endocrinology, Benign breast diseases etc.

Dr Wassilew is a Cardiothoracic Histopathologist with extensive experience in pediatric and adult cardiothoracic and MCS-related, as well as heart and lung transplantion pathology. Previous appointments include an Associate Professor and head of unit positions at some of the largest faculties for health and medical sciences in Europe. Played key role setting-up study designs while contributing to grant applications for multiple international projects. Called upon experience in working with forensic pathology in cases of sudden deaths. Extensive experience in under- and postgraduate teaching, educational content creation and medical event organisation, including the first ISHLT endorsed technology transfer meeting in Eastern Europe. Member of organizing committee of international meetings on artificial intelligence, blockchain and precision medicine. Currently pathology representative to the MCS nterdisciplinary network and member of the membership committee of the International Society of Heart and Lung transplantation, as well as associate editor for JHLT Open

Ching-Chih (Alberta) Huang, PharmD, MS, is a pharmacist, clinical researcher, and precision medicine professional with experience spanning pharmacogenomics, oncology, clinical bioinformatics, and translational research. She currently serves as Vice President of Strategic Partnerships & Clinical Innovation at Predictiv Care, where she contributes to the development and implementation of precision health solutions integrating genomic, molecular, and clinical data. Dr. Huang earned her Doctor of Pharmacy degree from Taipei Medical University and a Master of Science in Biotechnology with a concentration in Bioinformatics from Johns Hopkins University. Her clinical background includes hospital pharmacy practice and specialized oncology pharmacy experience, with expertise in chemotherapy management, medication safety, and individualized patient care. Her research interests focus on pharmacogenomics, precision oncology, genomic biomarkers, liquid biopsy, and the application of real-world clinical and genomic data to personalized medicine. Her recent research has investigated genetic predictors of cisplatin-induced nephrotoxicity using large-scale whole-genome sequencing and clinical datasets. She is particularly interested in translating genomic discoveries into practical clinical decision-support tools that improve medication selection, risk prediction, and patient outcomes.

Maham Ansari is Senior Director of Regulatory Affairs at Precision for Medicine, where she heads up companion diagnostic co development programs with a focus on gene therapy. She brings extensive global regulatory leadership experience across major multinationals, including Qiagen, as well as high growth start ups. Her expertise includes developing global regulatory strategies to secure approvals in the US, Europe, and other regions, supporting the full lifecycle of complex medical devices and IVDs. She is well versed in leading challenging conversations with Regulatory Authorities and has a proven track record in bringing complex novel diagnostics to market. Maham holds an undergraduate degree in Chemical Engineering from the University of Toronto and a master’s degree from Johns Hopkins University.

Dr. Anil A. Bajnath, MD, MBA is a physician, educator, entrepreneur, and leader in precision and integrative medicine. He serves as an Adjunct Assistant Professor in the Department of Clinical Research and Leadership at the George Washington University School of Medicine and Health Sciences, where he contributes to advancing education in integrative and precision healthcare. Dr. Bajnath is the Founder and President of the American Board of Precision Medicine (ABOPM), a nonprofit organization dedicated to advancing physician education, board certification, interdisciplinary collaboration, and research in precision medicine. Through ABOPM, he is leading initiatives to bridge the gap between emerging scientific discoveries and real-world clinical practice by integrating genomics, multi-omics, artificial intelligence, systems biology, and personalized healthcare into medical education and patient care. With a background spanning clinical medicine, molecular biology, and business leadership, Dr. Bajnath is passionate about transforming healthcare through innovation, prevention, and individualized treatment strategies. His work focuses on equipping healthcare professionals with the knowledge and tools needed to implement precision medicine across diverse clinical settings while fostering global collaboration among clinicians, researchers, and industry leaders dedicated to shaping the future of personalized healthcare.

Dr. Smitha Chacko is a board-certified oncology clinical pharmacy specialist with experience in hematology/oncology pharmacy practice, patient education, quality improvement, and professional mentorship. She earned her Doctor of Pharmacy degree from St. John’s University and her Master of Business Administration from Hofstra University. Dr. Chacko is committed to advancing patient-centered oncology care through comprehensive medication management, direct counseling of patients and families, and the delivery of educational and supportive resources. Her clinical focus includes the prevention, recognition, and management of adverse drug reactions to improve treatment adherence, safety, and patient outcomes. She also serves as a preceptor to pharmacy students and postgraduate pharmacy residents seeking to build their knowledge and clinical skills in hematology and oncology. In addition, Dr. Chacko has experience helping organize continuing education conferences for healthcare professionals and supporting interdisciplinary learning. Her professional interests include medication utilization reviews, retrospective clinical and quality studies, and leading data-driven quality initiatives designed to optimize medication use and improve outcomes. An active member of the Hematology/Oncology Pharmacy Association (HOPA), Dr. Chacko serves as a media ambassador and supports initiatives such as the Cancer Buddy web application.

Dr. Ngoni Faya is an early career clinical laboratory geneticist, educator, and researcher advancing genomic medicine and health equity. He serves as Medical Director at Knight Diagnostics Laboratories and Assistant Professor at Oregon Health & Science University, leading clinical test development and molecular genetics and cytogenetics interpretation, with a focus on expanding diagnostic access for all. Dr. Faya completed his PhD in Genetics at Massey University, New Zealand, followed by a Postdoctoral Fellowship at Genomics Aotearoa/University of Otago and a Clinical Fellowship in Laboratory Genetics and Genomics at Cincinnati Children's Hospital, where he served as Chief Fellow in the Medical Genetics Fellowship Program. He also holds an MSc in Bioinformatics and Computational Biology from Rhodes University and a BSc Honours in Biochemistry from the University of Fort Hare, South Africa. His research spans rare disease diagnosis, variant curation, and cancer genomics. He is an active member of the American College of Medical Genetics, the American Cytogenomics Conference, and the Cancer Genomics Consortium, and serves on the ClinGen X-linked Inherited Retinal Disease Variant Curation Expert Panel, helping shape gene-specific curation frameworks used internationally. A recipient of the 2025–26 Rare Diseases Clinical Research Scholar's Program award, Dr. Faya is committed to mentorship and improving equitable access to genetic testing for rare and inherited conditions worldwide.

After graduating the Tbilisi State Medical University with distinction in 2001, worked in the Ministry of Healthcare in the field of international and public relations Before moving to Business, hold the position of the Head of International Relations Department within the Ministry of Labor, Health and Social Affairs of Georgia In 2008 - founded the first Medical Tourism Company "Medtourgeorgia" in Georgia 2012 - Medical Tourism American Association board member 2016 - Author of the first manual for the medical tourism facilitators - "Medical Tourism as my Lifestyle" 2012-2015 Leaded the TV series about the International Medical Facilities from Turkey, Germany, Austria. Latvia, Ukraine, Israel, India, China, Japan, Span, Greece. 2017 - special award for the personal input in the Medical Tourism Industry development in Dubai, UAE Author of the concept of "Professional Consultation for Treatment Abroad Issues", founder of LTD Ratiani Consulting Author of the several international projects in EU, CIS, Turkey and Asian Region 2019 Founder and President of Georgian Medical Tourism Council as the main country representing body on the international scene. Medical Tourism International Expert, Opinion Leader and Strategy developer with the experience of more than 15 years. Speaking Georgian, Russian, English, German and Spanish languages. With the Medical, International Relations and Business management educational background, Global Healthcare Diplomacy outstanding representative.

Bettina van Wylich-Muxoll Co-Founder & Managing Partner, BioAgeDiagnostics Bettina van Wylich-Muxoll is an international healthcare executive and entrepreneur with more than 15 years of experience spanning precision medicine, digital health, diagnostics, preventive healthcare and commercialisation. She is Co-Founder and Managing Partner of BioAgeDiagnostics, a European longevity healthcare company focused on translating advances in biological ageing and precision diagnostics into clinically relevant and commercially scalable solutions. BioAgeDiagnostics works with healthcare providers and diagnostic innovators to advance personalised prevention and healthy longevity and is building the infrastructure for Biological Outcomes Intelligence. Prior to founding BioAgeDiagnostics, Bettina held international leadership roles across healthcare and digital health, including at Novo Nordisk, Monsenso and Valida Health, with a particular focus on bringing healthcare innovation from science and technology into clinical practice and international markets. Her current work focuses on the evolution of precision longevity medicine, biological ageing, next-generation diagnostics and multi-biomarker approaches to understanding health trajectories and intervention outcomes. She is particularly interested in how healthcare can transition from predominantly reactive disease management towards earlier detection, personalised prevention and measurable improvements in healthspan.

Víctor Maestre Ramírez is a multidisciplinary researcher, educator, and cybersecurity professional whose work bridges precision medicine, genomics, biotechnology, and digital innovation. His academic background includes advanced studies at Harvard Medical School, where he pursued education in medicine as well as advanced statistics and quantitative methods applied to biomedical research, strengthening his expertise in data-driven healthcare and translational science. He is the founder of the Ludgenstein Institute, an educational organization dedicated to advancing excellence in networking, cybersecurity, genetic engineering, and synthetic biology through interdisciplinary training and research. The institute promotes the convergence of computational sciences, life sciences, and emerging technologies to prepare professionals for the next generation of scientific and technological challenges. Víctor was awarded a Synthetic Biology Scholarship by Biotecnika, recognizing his commitment to innovation in biotechnology and synthetic biology. He has also contributed to NASA-related research initiatives, collaborating on projects at the intersection of life sciences, technology, and human health in extreme environments. His research interests include precision medicine, genomics, bioinformatics, synthetic biology, artificial intelligence in healthcare, and cybersecurity for medical systems. Through his multidisciplinary expertise, he is committed to fostering international collaboration and accelerating the translation of scientific discoveries into personalized healthcare solutions.

Prof. Dr. Gülbu Tanrıverdi is a Professor of Public Health Nursing at Çanakkale Onsekiz Mart University. Having completed her education in both nursing and sociology, Tanrıverdi is recognized as one of the pioneering academics in the field of transcultural nursing in Türkiye. She has edited seven books, authored more than 40 book chapters, and published over 80 scientific articles in this field. Tanrıverdi introduced the “Environment-Focused Cultural Competence Model,” the first nursing model developed in Türkiye, to the literature. She has delivered national and international seminars on cultural competence and cultural sensitivity, contributing to the development of culture-based care approaches in nursing, midwifery, and health sciences. For her work in transcultural nursing, she received the FTNSS Award, which was granted to a nurse in Türkiye for the first time. As the first faculty member of her department, Tanrıverdi served as department chair for many years and has also held several administrative positions, including directorships, ethics committee memberships, and numerous academic, scientific, and administrative commission roles. She was actively involved for many years in the ÇOMÜ Women’s Studies Application and Research Center and currently serves as a member. She is also the founding chair of the Transcultural Nursing Association in Çanakkale.

David Kasteler is the founder and CEO of Regenerative Research Group, a global biologics supply and clinic enablement company supporting more than 500 clinic partners worldwide. Over the past two decades, David has built and scaled international companies employing more than 700 people across 13 countries, developed more than 30 health products, and generated over $200 million in cumulative revenue. His interest in regenerative medicine began more than a decade ago after stem cell and biologics treatments helped him resolve persistent knee pain and avoid surgery. Since then, he has become a leading advocate for the responsible advancement and practical application of regenerative biologics. David also co-founded Discover Biologics Institute, an independent 501(c)(3) nonprofit focused on practitioner education and training. He is the author of the forthcoming book Beyond Repair and will begin a PhD program in fall 2026.

Roya Khosravi-Far, Ph.D., PLD, is the co-founder, President, and CEO of InnoTech Precision Medicine, where she lead the development of next-generation in vitro diagnostics. An internationally recognized leader in translational and precision medicine, she has over 30 years of experience spanning academia and industry. Dr. Khosravi-Far served as a Professor of Pathology at Harvard Medical School for 17 years and has held leadership roles at Ziopharm Oncology and Accurome Health. She is an inventor of InnoTech’s multi-omics platform technology and has authored over 75 peer-reviewed publications and three books. She holds a Ph.D. in Genetics and Molecular Biology from the University of North Carolina, Chapel Hill, and completed her Postdoctoral Fellowship in Cancer Immunology at MIT. Her work focuses on democratizing healthcare through innovative, accurate diagnostic solutions.

Dr Kieran Breen is Head of Research and Development at St Andrew's Healthcare, one of the UK's largest specialist mental health providers, where he leads a research strategy built around precision medicine and personalised healthcare. With more than 30 years' experience spanning neuroscience, medicines regulation and healthcare innovation, he is committed to tailoring care to the individual patient and translating research into measurable clinical benefit. Central to his work is the responsible use of patient data in mental health research. Dr Breen has long championed the development and utilisation of patient data registries, enabling large-scale, real-world evidence to inform diagnosis, patient stratification and treatment decisions. He integrates biomarkers, bioinformatics and digital health tools to better understand complex conditions and personalise interventions in neuropsychiatric and secure care settings. His expertise extends firmly into the regulatory field. A member of several European Medicines Agency working groups, he has also advised the European Commission, and writes regularly on how regulators evaluate the benefit and risk of new therapies, including the growing role of genetic testing in determining treatment eligibility.

Dr. Lior Shaltiel is an awarded executive and scientist with a wealth of multidisciplinary international experience, specializing in innovative drug delivery systems. Since 2021, serving as the CEO and Director at NurExone Biologic Inc., an Canadian-Israeli biopharmaceutical company (TSXV:NRX) (OTCQB: NRXBF) at the forefront of utilizing advanced exosome technologies for the treatment of Spinal Cord Injury and traumatic nerve injury indications through minimally invasive administration. In 2015, Dr. Shaltiel founded and currently leads as the Academic Head of the BioMed-MBA program at the Hebrew University Business School (HUBS), where he bridges academic knowledge with entrepreneurial success. With a strong background in the industry, Dr. Shaltiel leverages his expertise to seize investment opportunities. Recently, he assumed the role of Co-Chairman of the MedTech division at the Israeli Association of Engineers, further solidifying his commitment to innovation and advancement in the field and the ecosystem

Shin Kawamata studied physics at Kyoto University, Japan (1975-1981) and medicine at Kobe University, Japan (1984-1990). He started his career as a medical doctor (hematology) and received a Ph.D. degree from Kyoto University (1998). He developed various human leukemia models in SCID mice in his post-doctoral period at Systemix Co., Palo Alto USA, and Stanford University (1999-2001). He became the chief scientist of Regenerative Medicine Research Unit and the general manager of the Cell Processing Facility at Foundation for Biomedical Research and Innovation (FBRI) (2002-2014) and the Director of R&D Center for Cell Therapy (RDC) (2015-2023). He has also served as aProject Professor at the Graduate School of Science, Technology and Innovation, Kobe University (2023–present). Hechairsthe ISCT reginal meeting in Singapore 2026. He is currently interested in the introduction of agent AI and Digital Twin at Cell Geneproduct manufacturing sites.

Dr Badgaiyan is Professor and Chairman of the Department of Psychiatryat Texas Tech University Health Sciences Center. He completed psychiatry residency training at Harvard Medical School and worked as a member of faculty at Harvard Medical School for over 10 years. He then moved to other academic centers to gain experience of leadership. He worked as the Chairman of psychiatry department at a Mt Sinai Hospital in New York city, Chief of Psychiatry at South Texas Veterans Healthcare Systemin San Antonio and Chairman of Psychiatry at Case Western Reserve University before moving back to Texas. As a leader he was instrumental in growing academic and clinical activities of departments and made the departments financially viable. Heis international expert in neuroimaging and is widely known for developing aunique brain imaging technique for detection, mappingand measurement ofneurotransmitters released acutely in the human brain during the brain processing of mental activities. His research is focused primarily on addiction and dysregulation of dopamine neurotransmission in psychiatric and neurological conditions. Dr Badgaiyan hasreceived several prizes and awards including theprestigious Solomon Prize of Harvard University and B.K.Anand National Research Prize in India. Dr Badgaiyan is recipient of many multimillion dollar research grants. He has published over 300 peer-reviewed scientific papers and works as the Editor-in-Chief of several per-reviewed international journals. He is the author of a popular book, ‘Neuroscience of the Nonconscious Mind’published by Elsevier/Academic Press.

Dr. Rainier Nery Mozo, MD, FPCP, FPCHA, MMHA is a Philippine internal-medicine physician and healthcare leader working at the intersection of genomic, precision, and regenerative medicine. He holds a Postgraduate Diploma in Genomic Medicine and Healthcare (with Merit) from the University of South Wales and is a Fellow of the Philippine College of Physicians, with membership in the American and European Societies of Human Genetics, the International Society for Cell & Gene Therapy (ISCT), and the International Society for Stem Cell Application (ISSCA). He serves as President & CEO of Clearbridge Health Philippines, Co-Founder of the Philippine Institute of Regenerative and Innovative Medicine, and Associate Professor of Internal Medicine and Medical Research at the Pamantasan ng Lungsod ng Maynila (University of the City of Manila) College of Medicine. His research applies machine-learning classification models to Filipino patients with Metabolic Dysfunction-Associated Steatotic Disease (MASLD) and Type 2 Diabetes Mellitus, advancing data-driven, personalized approaches to cardiometabolic disease in Southeast Asian populations. Dr. Mozo’s work integrates precision diagnostics, regenerative cellular therapeutics, and health-systems innovation, with a consistent focus on translating personalized medicine into practical clinical care for Philippine and Southeast Asian settings.

Thomas H. Jensen has served as Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023 and has been a member of the Board of Directors since July 2022. He has been involved with the Company since its founding in 2004, holding leadership roles across technology, laboratory operations, investor relations, financing, and business development. Prior to becoming CEO, he served as Senior Vice President of Investor Relations and previously led the Company’s technology functions, including as Chief Technology Officer. Mr. Jensen established Allarity’s laboratories in Denmark, and his scientific work in molecular biology, including reproducible RNA extraction and downstream processing methods, has contributed to the foundation of Allarity’s DRP® platform for high-resolution analysis of cancer patient biopsies. He also serves on the Board of Cardeon AB. Mr. Jensen holds a BSc in Biology from the Technical University of Denmark.

Dr. Bernd Blobel studied Mathematics, Technical Cybernetics and Electronics, Bio-Cybernetics, Physics, Medicine and Informatics at the University of Magdeburg and other universities in the former GDR. He received his PhD in Physics with a neurophysiological study. Furthermore, he performed the Habilitation (qualification as university professor) in Medicine and Informatics. He was Head of the Institute for Biometrics and Medical Informatics at the University of Magdeburg, and thereafter Head of the Health Telematics Project Group at the Fraunhofer IIS in Erlangen. Thereafter, he acted until his retirement as Head of the German National eHealth Competence Center as well as Head of the globally unique International Interdisciplinary PhD and PostDoc Collegeat the University of Regensburg. He was and is still leadingly involved in many countries health digitalization as well as electronic health record strategy. He published more than 600 papers, published/edited many books and supervised a big number of PhD students from all around the world. He was German Representative to many SDOs such as HL7, ISO, CEN, OMG, IEEE, ASTM, SNOMED, etc., also chairing the national mirror groups. Furthermore, he still engaged in international higher education.He is Fellow of several international academies and played specific roles in global organizations such as WHO, European Commission, UNESCO, etc. He is also Visiting Professor at the Charles University in Prague. His extended publication list is available at https://epub.uni-regensburg.de/view/people/Blobel=3ABernd=3A=3A.html.

Kenneth Blum, PhD is Chairman of the Kenneth Blum Behavioral & Neurogenetic Institute, Austin, Texas, USA, and an internationally recognized neuroscientist, pharmacologist, and pioneer in neurogenetics, precision psychiatry, and addiction medicine. His research has significantly advanced the understanding of the genetic and neurobiological mechanisms underlying Reward Deficiency Syndrome (RDS), dopamine signaling, addiction, and brain reward pathways. Over a distinguished career spanning several decades, Dr. Blum has held numerous academic, scientific, and leadership positions and has served as Editor-in-Chief or editorial board member for multiple international scientific journals. He has authored and co-authored more than 1,170 peer-reviewed scientific publications, received over 50,000 citations (H-index: 113), and has been awarded more than 100 patents in the fields of neurogenetics, addiction medicine, precision genomics, and therapeutic technologies. Dr. Blum's current research focuses on precision genomics, pharmacogenomics, multi-trait GWAS, dopamine homeostasis, personalized medicine, and novel therapeutic approaches for addiction, psychiatric disorders, obesity, and neurodegenerative diseases. His pioneering work continues to influence translational neuroscience and precision healthcare through the integration of genetics, molecular biology, and personalized therapeutic strategies.

In 2005 Sirma Todorova Angelova gained a Master degree at the University of Economics in Varna, Bulgaria and in 2011- a Master Degree of Dental Medicine at the Medical University Varna. From 2011 to 2018 she worked as an Assistant-Professor and since 2018 as a Chief Assistant-Professor at Medical University-Varna. In 2015 Angelova gained a Certificate of Specialization of Pediatric Dentistry. In 2017 she gained a postgraduate degree with the independent research: “Caries Risk Assessment and Prevention in Children Suffering from Some Renal Disorders”. In 2019 was issued her monograph “Epigenetic and Genetic Aspects of Oral Health in Children with Pyelonephritis”. In 2024 Sirma Angelova has held an academic degree of Associate Professor at Pediatric Dentistry at the Faculty of Dental Medicine, Medical University Varna. Angelova authored and co-authored more than 95 papers and reports and participated in more than 70 scientific congresses. Her research interests are related to the scopes of caries risk evaluation and its control in children; gingival disorders and their management in different periods of childhood; nutrition-oral health interrelations in children; dental prophylaxis; preventive Pediatric Dentistry; oral diseases associated diagnostic and prognostic capacities of saliva in children

Dr. Kadhim Alabady is an accomplished public health and epidemiology consultant with over 25 years of leadership experience across academic institutions, international agencies, and national health systems. He is a Fellow of the Faculty of Public Health (UK) and the Royal College of Physicians and Surgeons of Glasgow. Dr. Alabady holds a Doctorate in Public Health and Epidemiology, an MSc in Clinical Epidemiology, and an MPH—awarded by leading institutions in the Netherlands. He is also a certified Grade A Epidemiologist with the Netherlands Epidemiological Society. His career includes key roles with: • Academic Institutions: Erasmus University (Netherlands), Queen Mary University (UK), University of East Anglia (UK) • International Organizations: United Nations (US and KSA) • National Health Systems: UK NHS, Qatar National Health Authority, Dubai Health Authority His expertise spans research, strategy, and service design in areas such as non-communicable diseases (NCDs), mental health, cancer, and population health. Dr. Alabady has contributed extensively to public health research and policy, with published work in the UK and beyond.

Dr. Arun K. Garg, MD, PhD, FRCPC, is an internationally recognized physician, consultant medical biochemist, educator, and health systems leader with more than four decades of experience in laboratory medicine, healthcare innovation, and community health. He serves as Clinical Professor of Pathology at the University of British Columbia and Clinical Professor in the Faculty of Medicine at Simon Fraser University, Canada. Throughout his distinguished career, Dr. Garg has held several senior leadership roles within Fraser Health, including Executive Medical Director for Lower Mainland Pathology and Laboratory Medicine, Program Medical Director for Laboratory Medicine and Pathology, and Regional Director of Medical Biochemistry. He currently serves as Medical Director of the South Asian Health Institute, where he champions culturally informed approaches to chronic disease prevention and health equity. Dr. Garg is the Founder and President of the Canada India Network Society (CINS), an organization dedicated to strengthening Canada–India collaborations in healthcare, education, research, and innovation. His work focuses on advancing precision health through the integration of biochemical, cultural, and technological perspectives. A recipient of numerous national and international honors, Dr. Garg is widely recognized for his contributions to healthcare leadership, patient-centered care, global health collaboration, and community wellbeing.

Dr Joanne M. Hackett is Vice President and Global Head of Health System Services at IQVIA, where she leads global strategy and innovation at the intersection of healthcare systems, data, and transformation. She previously served as Chief Commercial Officer at Genomics England. A clinical academic, entrepreneur, and investor, Dr Hackett brings extensive global experience across start ups, public institutions, and Fortune 500 organisations. She is widely recognised for her ability to build innovation at scale, advance personalised medicine, and lead organisations through complex, fast moving change and integration. Her work is driven by a commitment to delivering novel, cost effective, and scalable healthcare solutions, with particular focus on prevention, open science, and citizen genomics. Drawing on experience across academic, clinical, and commercial environments, she is a trusted advisor to boards and leadership teams globally. Dr Hackett has received numerous international recognitions for her impact on healthcare innovation, including Healthcare Businesswomen’s Association Rising Star, CIO Look’s Top Six Influential Leaders in Healthcare, Accenture Life Sciences Leader of the Year, Freshfields Top 100 Most Influential Women, One HealthTech Top 70 Women in the NHS, Pharmaceutical Market Europe’s 30 Women Leaders in UK Healthcare, and BioBeat Top 50 Women in Biotech. A compelling and authentic speaker, Dr Hackett is known for combining strategic insight with personal resilience, championing the belief that meaningful and lasting change—organisational and societal—can be achieved even in the most complex environments.As a believer of ‘health = wealth’, Joanne is an internationally known yoga instructor.

Sima Ataollahi Eshkoor is a medical doctor with a PhD in Human Genetics from Universiti Putra Malaysia (2011) and extensive experience in healthcare and biomolecular research. Her work focuses on molecular and biological mechanisms underlying health outcomes and quality of life in human populations. She has published extensively on a range of disorders, including cognitive impairment and cancer. Her highly cited publication on mild cognitive impairment (MCI) in the Journal of Clinical Interventions in Aging has received over 600 citations, reflecting its significant impact on the field. With clinical experience in neurology, internal medicine, and age-related diseases, Dr. Sima has developed a strong understanding of the biological and environmental determinants of healthy aging. Her clinical background supports her ability to bridge scientific research and real-world clinical applications. Dr. Sima has collaborated internationally, mentored early-career researchers, contributed to peer review, and participated in the organization of scientific conferences. At the International Conference on Precision Medicine & Personalized Healthcare (PrecisionMed 2027), she will contribute expertise in advancing strategies to improve healthcare through the study of molecular changes across diverse populations.